Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan Said To Lack Infrastructure For Major Biotech Industry – Takeda President

This article was originally published in PharmAsia News

Executive Summary

Japan lacks the infrastructure and funding necessary to have a major biotechnology industry, according to the president of Takeda Pharmaceutical. Yasuchika Hasegawa said that moving beyond Japan's current status of limited biotech efforts requires more bioventure funds than the nation has and said the industry also is restricted by the current tax system and the lack of enough bio clusters. Japan's biotech ventures are characterized by their focus on just a few drugs or technologies in their pipelines, and Hasegawa said that moving beyond that would require being able to generate new revenue sources continually. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts